Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

RIGL Rigel Pharmaceuticals

1.150
+0.010+0.88%
Close 10/06 16:00 ET
1.1500.0000.00%
Pre Mkt Price 10/07 04:40 ET
High
1.180
Open
1.140
Turnover
1.83M
Low
1.130
Pre Close
1.140
Volume
1.58M
Market Cap
198.76M
P/E(TTM)
Loss
52wk High
3.600
Shares
172.84M
P/E(Static)
Loss
52wk Low
0.640
Float Cap
197.49M
Bid/Ask %
99.00%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.97
Historical Low
0.640
Dividend TTM
--
Div Yield TTM
--
P/B
-54.76
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.92%
Amplitude
4.39%
Avg Price
1.155
Lot Size
1
Float Cap
197.49M
Bid/Ask %
99.00%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.97
Historical Low
0.640
Dividend TTM
--
P/B
-54.76
Dividend LFY
--
Turnover Ratio
0.92%
Amplitude
4.39%
Avg Price
1.155
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
CEO: Mr. Raul R. Rodriguez
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...